Original Articles

Compliance for Genetic Screening in the Arab Population in Israel

Download PDF Print
Click on the icon on the upper right hand side for the article by Rivka Sukenik-Halevy, MD, Ulfat Abu leil-Zoabi, MA, Lilach Peled-Perez, MA, Joel Zlotogora, MD, PhD and Stavit Allon-Shalev, MD.
IMAJ 2012: 14: September: 538-542
Abstract

Background: Genetic screening tests for cystic fibrosis (CF), fragile X (FRAX) and spinal muscular atrophy (SMA) have been offered to the entire Arab population of Israel in the last few years. Since 2008, screening for CF is provided free of charge, but for FRAX and SMA the screening is privately funded with partial coverage by complementary health insurance programs.


Objectives: To assess the compliance of Arab couples for genetic screening tests, and the factors that affect their decisions.


Methods: We analyzed compliance for genetic screening tests at the Emek Medical Center Genetic Institute, and in outreach clinics in four Arab villages. We enquired about the reasons individuals gave for deciding not to undergo testing. We also assessed the compliance of these individuals for the triple test (a screening test for Down syndrome).


Results: Of the 167 individuals included in our study, 24 (14%) decided not to be tested at all. Of the 143 (86%) who decided to be tested, 109 were tested for CF only (65%) and 34 (20%) for SMA and FRAX (as well as CF). The compliance rate for the triple test was 87%. Technical reasons, mainly financial issues, were the most significant factor for not undergoing all three tests.


Conclusions: The compliance of the Arab community for genetic testing for SMA and FRAX is extremely low. We believe that this low utilization of screening is due to economic reasons, especially when a complementary health plan has not been acquired, and largely reflects the perception that these tests are less important since they are privately funded.